This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Anticoagulants Industry

9. PRODUCT INTRODUCTIONS/APPROVALS IN RECENT PAST- A PERSPECTIVE

BUILDER II-60

GSK Receives EU Approval for Arixtra® II-60

Pradaxa Receives FDA Approval II-60

Canyon Pharmaceuticals Introduces Iprivask II-60

Teva Receives FDA's Tentative Approval for Argatroban II-60

TrimGen Receives FDA 510(k) Approval for Marketing eQ-PCR™ LC

Warfarin Genotyping Kit II-61

Lundbeck Launches ATryn® Commercially in the US II-61

The Medicines Co Receives European Approval for Angiox (

Bivalirudin) II-61

 

10. RECENT INDUSTRY ACTIVITY II-62

FDA Issues Complete Response Letter for Eliquis's New Drug

Application II-62

FDA Issues Complete Response Letter to Rivaroxaban's (Xarelto)

NDA for ACS II-62

US FDA Extends Date for Eliquis' New Drug Application II-62

Pradaxa® Receives NICE Recommendation II-62

BioInvent and ThromboGenics Discontinue Development of TB-402 II-62

Watson Receives Stay Order on Preliminary Injunction II-63

FDA Assigns Priority Review for Xarelto Supplemental NDA II-63

Portola Pharmaceuticals Re-Acquires Rights to Betrixaban II-63

FDA Accepts New Drug Application for ELIQUIS® II-63

Astellas Pharma Halts Development of Anticoagulant II-63

Sanofi-Aventis Changes Name to Sanofi II-63

 

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-64

Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim II-64

Sagent Pharmaceuticals Secures FDA Approval for Heparin Sodium

Injection II-64

Biomet Acquires Cytosol Laboratories II-64

Portola Inks $470 M Agreement with Merck for Phase II

Anticoagulant II-64

Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma II-65

Nuvelo and ARCA biopharma Merge II-65

 

12. FOCUS ON SELECT GLOBAL PLAYERS II-66

Bayer Healthcare AG ( Germany) II-66

Boehringer Ingelheim ( Germany) II-66

Bristol-Myers Squibb Company ( USA) II-66

Eisai Inc. ( USA) II-67

GlaxoSmithKline plc (UK) II-67

LEO Pharmaceutical Products ( Denmark) II-67

Mitsubishi Tanabe Pharma Corporation ( Japan) II-68

Pfizer Inc. ( USA) II-68

Sanofi ( France) II-68

Teva Pharmaceutical Industries Ltd ( Israel) II-69

Teva Pharmaceuticals USA ( USA) II-69

 

5 of 15

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs